HomeAI · summaries
Storia in 3 fonti
FDA grants priority review to Enspryng for thyroid eye disease
The FDA granted priority review to a supplemental biologics license application for Enspryng for thyroid eye disease, according to a press release from Genentech. Enspryng (satralizumab) is currently approved for the treatment of neuromyelitis optica spectrum disorder in patients who are aquaporin-4 antibody positive. If approved, it would become the first at-home subcutaneous treatment option
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA approves Lumvoa for thyroid eye disease
The FDA approved Lumvoa, a full insulin-like growth factor 1 receptor antagonist, for the treatment of thyroid eye disease, according to a press release from Viridian…
- ·
benzinga.com
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease - Virid
FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.
